Abstract Body

Background: Methamphetamine (meth) is a widely used recreational drug in North America, especially among HIV-infected men who have sex with men (MSM), and is associated with worse health outcomes in HIV infected persons. Methodology: Fifty HIV-infected MSM on long-term antiretroviral therapy (ART) (median 3.8 years) with plasma HIV RNA <50 copies/ml and who were enrolled in a prospective clinical trial to reduce sexually transmitted infections were studied. Meth and other drug use in the past month were assessed at baseline with a self-administered internet-based survey along with other risk behaviors. Levels of immune activation (CD45RA-CD38+) and proliferation (Ki67+) of CD4+ and CD8+ T-cells subsets were determined from frozen peripheral blood mononuclear cells (PBMC) by multicolor flow-cytometry. Total HIV DNA (pol), 2-long terminal repeat (2-LTR), and cellular HIV RNA (unspliced and multiply-spliced encoding for tat/rev) were measured in PBMC by droplet digital PCR. Using non-parametric statistics, we investigated associations between recent use of meth with immune activation and proliferation of subsets of CD4+ and CD8+ T-cells in blood, CD4 count, time on ART, and with levels of HIV DNA and cellular HIV RNA. Results: Twelve of 50 (24%) MSM reported meth use in the past month. Meth use was significantly associated with higher levels of immune activation (CD45RA-CD38+) and proliferation (Ki67+) of total CD4+ T-cells (both P<0.05), and with higher levels of proliferating CD8+ T-cells (P<0.01), in each analyzed subset (i.e. naive, central memory, transitional memory, effector memory CD8+ T-cells). Recent meth use was also associated with a trend towards higher levels of proviral HIV DNA reservoir (median of 2.09 vs. 1.83 log10 copies/million CD4+ T-cells, P=0.09) and higher levels of multiplyspliced cellular HIV RNA transcripts compared to those not using meth (P=0.06). Use of other drugs (cannabis, cocaine, other ‘club’ drugs, alcohol), CD4 counts and time on ART were not associated with any differences in immunologic or virologic markers. Self-reported adherence to ART was not significantly different between meth users and non-meth users (P=1.0). Conclusions: Self-reported meth use by HIV-infected MSM on long-term ART with fully suppressed plasma HIV RNA levels was uniquely associated with increased T-cell immune activation and proliferation, both of which could explain meth-related co-morbidities. Meth users might also have a greater HIV DNA reservoir and residual HIV RNA replication than non-meth users, but this observation and the underlying immunomodulatory mechanisms of meth in HIV-suppressed individuals need to be confirmed in a longitudinal study including a larger population.